Discovery of orally bioavailable inhibitors of MALT1 with in vivo activity for psoriasis

被引:2
作者
Asaba, Ken Nunettsu [1 ]
Okimura, Keiichi [1 ]
Adachi, Yohei [1 ]
Tokumaru, Kazuyuki [1 ]
Goto, Yasufumi [1 ]
Fujii, Shigeo [1 ]
Watanabe, Akira [1 ]
Sakai, Chizuka [1 ]
Sakurada, Eri [1 ]
Amikura, Kazutoshi [1 ]
Aoki, Takumi [1 ]
机构
[1] Toray Industries Ltd, Pharmaceut Res Labs, 6-10-1 Tebiro, Kamakura, Kanagawa 2488555, Japan
关键词
MALT1; inhibitors; Structure activity relationship; Psoriasis; KAPPA-B ACTIVATION; PARACASPASE MALT1; LYMPHOMA; CLEAVAGE; CARD14;
D O I
10.1016/j.bmcl.2023.129155
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
We report the design, synthesis, and biological activity of a series of compounds that exhibit potent mucosa-associated lymphoid tissue lymphoma translocation 1 (MALT1) inhibition. Structural transformation of the substructures of a starting compound gave amidomethyl derivatives and sulfonylguanidine derivatives that exhibited potent inhibition of MALT1. Compound 37 had good oral bioavailability and showed anti-psoriatic activity in an imiquimod-induced psoriasis mouse model after oral administration.
引用
收藏
页数:10
相关论文
共 27 条
[1]   The paracaspase MALT1 mediates CARD14-induced signaling in keratinocytes [J].
Afonina, Inna S. ;
Van Nuffel, Elien ;
Baudelet, Griet ;
Driege, Yasmine ;
Kreike, Marja ;
Staal, Jens ;
Beyaert, Rudi .
EMBO REPORTS, 2016, 17 (06) :914-927
[2]   MALT1-a universal soldier: multiple strategies to ensure NF-κB activation and target gene expression [J].
Afonina, Inna S. ;
Elton, Lynn ;
Carpentier, Isabelle ;
Beyaert, Rudi .
FEBS JOURNAL, 2015, 282 (17) :3286-3297
[3]   Structure?activity relationship studies of 3-substituted pyrazoles as novel allosteric inhibitors of MALT1 protease [J].
Asaba, Ken Nunettsu ;
Adachi, Yohei ;
Tokumaru, Kazuyuki ;
Watanabe, Akira ;
Goto, Yasufumi ;
Aoki, Takumi .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2021, 41
[4]   T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-κB inhibitor A20 [J].
Coornaert, Beatrice ;
Baens, Mathijs ;
Heyninck, Karen ;
Bekaert, Tine ;
Haegman, Mira ;
Staal, Jens ;
Sun, Lijun ;
Chen, Zhijian J. ;
Marynen, Peter ;
Beyaert, Rudi .
NATURE IMMUNOLOGY, 2008, 9 (03) :263-271
[5]   CYANOGUANIDINE-THIOUREA EQUIVALENCE IN DEVELOPMENT OF HISTAMINE H-2-RECEPTOR ANTAGONIST, CIMETIDINE [J].
DURANT, GJ ;
EMMETT, JC ;
GANELLIN, CR ;
MILES, PD ;
PARSONS, ME ;
PRAIN, HD ;
WHITE, GR .
JOURNAL OF MEDICINAL CHEMISTRY, 1977, 20 (07) :901-906
[6]   MALT1 Small Molecule Inhibitors Specifically Suppress ABC-DLBCL In Vitro and In Vivo [J].
Fontan, Lorena ;
Yang, Chenghua ;
Kabaleeswaran, Venkataraman ;
Volpon, Laurent ;
Osborne, Michael J. ;
Beltran, Elena ;
Garcia, Monica ;
Cerchietti, Leandro ;
Shaknovich, Rita ;
Yang, Shao Ning ;
Fang, Fang ;
Gascoyne, Randy D. ;
Angel Martinez-Climent, Jose ;
Glickman, J. Fraser ;
Borden, Katherine ;
Wu, Hao ;
Melnick, Ari .
CANCER CELL, 2012, 22 (06) :812-824
[7]   Malt1-dependent RelB cleavage promotes canonical NF-κB activation in lymphocytes and lymphoma cell lines [J].
Hailfinger, Stephan ;
Nogai, Hendrik ;
Pelzer, Christiane ;
Jaworski, Maike ;
Cabalzar, Katrin ;
Charton, Jean-Enno ;
Guzzardi, Montserrat ;
Decaillet, Chantal ;
Grau, Michael ;
Doerken, Bernd ;
Lenz, Peter ;
Lenz, Georg ;
Thome, Margot .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (35) :14596-14601
[8]   A patent review of MALT1 inhibitors (2013-present) [J].
Hamp, Isabel ;
O'Neill, Thomas J. ;
Plettenburg, Oliver ;
Krappmann, Daniel .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2021, 31 (12) :1079-1096
[9]   Psoriasis mutations disrupt CARD14 autoinhibition promoting BCL10-MALT1-dependent NF-κB activation [J].
Howes, Ashleigh ;
O'Sullivan, Paul A. ;
Breyer, Felix ;
Ghose, Ashavari ;
Cao, Li ;
Krappmann, Daniel ;
Bowcock, Anne M. ;
Ley, Steven C. .
BIOCHEMICAL JOURNAL, 2016, 473 :1759-1768
[10]   Clinical and Genetic Heterogeneity of CARD14 Mutations in Psoriatic Skin Disease [J].
Israel, Laura ;
Mellett, Mark .
FRONTIERS IN IMMUNOLOGY, 2018, 9